Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
52 hedge funds and large institutions have $299M invested in Avadel Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 6 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
271% more capital invested
Capital invested by funds: $80.5M → $299M (+$218M)
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
49% more funds holding
Funds holding: 35 → 52 (+17)
12% more call options, than puts
Call options by funds: $925K | Put options by funds: $825K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$16.2M |
| 2 |
BC
Broadfin Capital
New York
|
+$16.1M |
| 3 |
Jennison Associates
New York
|
+$16.1M |
| 4 |
Millennium Management
New York
|
+$11.6M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$631K |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$582K |
| 3 |
CCI
Columbus Circle Investors
|
-$468K |
| 4 |
BCM
Bourgeon Capital Management
Darien,
Connecticut
|
-$193K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$116K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $1K | +$1.07K | +100 | New |
|
|
52
Invesco
Atlanta,
Georgia
| – | -$631K | -78,346 | Closed |
|
|
CCI
53
Columbus Circle Investors
| – | -$468K | -58,132 | Closed |
|
|
VKH
54
Virtu KCG Holdings
New York
| – | -$116K | -14,478 | Closed |
|
|
BWP
55
Baldwin Wealth Partners
Marion,
Massachusetts
| – | -$101K | -12,600 | Closed |
|
|
JMFC
56
J.M. Forbes & Co
Boston,
Massachusetts
| – | -$88K | -11,000 | Closed |
|
|
JIC
57
Joel Isaacson & Co
New York
| – | -$2K | -210 | Closed |
|
58
Ameriprise
Minneapolis,
Minnesota
| – | -$107 | -10 | -48% |
|
AVDL Hedge Fund Activity: Q1 2014 in Review
52 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2014, worth a combined $299M — up 271% from $80.5M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AVDL positions and 6 closed out — a net gain of 17 holders — while 15 added to existing stakes and 7 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $16.2M. The largest seller was Invesco, exiting entirely with an estimated $631K sold.
- 52 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2014, up from 35 in Q4 2013.
- Funds reported $299M of Avadel Pharmaceuticals stock for Q1 2014, up 271% quarter-over-quarter.
- 23 funds opened new Avadel Pharmaceuticals positions in Q1 2014 and 6 closed out, a net change of +17 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2014 was JP Morgan Chase, an estimated $16.2M added.
- The largest Avadel Pharmaceuticals seller in Q1 2014 was Invesco, an estimated $631K sold.
Based on aggregated 13F filings for Q1 2014.